The Claim
In aged mdx mice with advanced Duchenne muscular dystrophy, serum creatine kinase levels remain elevated following BLS-M22 treatment, with a statistically significant reduction observed at 8 weeks but not at 12 weeks, indicating transient or incomplete attenuation of muscle damage.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In aged mice with a severe form of muscular dystrophy, a treatment called BLS-M22 reduces a marker of muscle damage at 8 weeks but not at 12 weeks, meaning the protective effect does not last.
See the scientific wording
In aged mdx mice with advanced Duchenne muscular dystrophy, serum creatine kinase levels remain elevated despite BLS-M22 treatment, with a statistically significant reduction only at 8 weeks but not at 12 weeks, suggesting transient or incomplete protection against muscle damage.
The immune system makes antibodies that block a protein called myostatin, which normally limits muscle growth. Blocking myostatin temporarily reduces muscle tearing and enzyme leakage into the blood, but it does not fix the underlying weakness in the muscle membrane, so damage returns over time.
What the research says
1 studyThe probiotic treatment helped reduce a muscle damage marker in mice after 8 weeks, but we don’t know if it still worked at 12 weeks — and since the muscles didn’t get stronger or less scarred, it probably didn’t fix the problem long-term.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.